OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Shroff on Remaining Unmet Needs for Patients With HCC

October 11th 2022

Rachna T. Shroff, MD, MS, discusses remaining unmet needs for patients with hepatocellular carcinoma.

Dr. Kim on the Evolution of Frontline Treatment in HCC

October 11th 2022

Richard Kim, MD, discusses the evolution of frontline treatment in hepatocellular carcinoma.

Dr. Ali on Key Findings From the Phase 1 Study of Selinexor Plus Ruxolitinib in Myelofibrosis

October 11th 2022

Haris Ali, MD, discusses a phase 1 dose-escalation trial investigating the administration of selinexor in combination with ruxolitinib for patients with treatment-naïve myelofibrosis.

Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian Cancer

October 11th 2022

Antonio Gonzalez-Martin, MD, PhD, discusses new long-term progression-free survival data from the phase 3 PRIMA trial in advanced ovarian cancer.

Dr. Kruse on the Effects of the MAINTAIN Trial on HR+/HER2- Breast Cancer Treatment

October 11th 2022

Megan Kruse, MD, discusses the real-world effects of the phase 2 MAINTAIN trial on treatment in advanced hormone receptor–positive, HER2-negative breast cancer.

Dr. Hewitt on Considerations for Conservation Vs Mastectomy in Breast Cancer

October 11th 2022

Kelly Hewitt, MD, discusses treatment considerations for breast conservation vs mastectomy in breast cancer.

Dr. Danilov on the Next Steps for Researching Noncovalent BTK Inhibitors in MCL

October 11th 2022

Alexey V. Danilov, MD, PhD, discusses the next steps for researching noncovalent BTK inhibitors in mantle cell lymphoma.

Dr. Pinilla-Ibarz on the Benefit of BTK Inhibitors in CLL

October 11th 2022

Javier Pinilla-Ibarz, MD, PhD, discusses the benefit of utilizing BTK inhibitors in chronic lymphocytic leukemia.

Dr. Schram on the Efficacy of RLY-4008 in FGFR2+ Cholangiocarcinoma

October 10th 2022

Alison Schram, MD, discusses the efficacy and safety of RLY-4008 in patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Dr. Kadia on E-selectin as a Target in the Treatment of AML

October 10th 2022

Tapan M. Kadia, MD, discusses the use of E-selectin as a target for treatment in acute myeloid leukemia.

Dr. Cohen on AEs Associated with BTK Inhibitors in CLL

October 7th 2022

Jonathon B. Cohen, MD, MS, discusses the adverse effects associated with BTK inhibitors in chronic lymphocytic leukemia.

Dr. Goetz on the Clinical Significance of Lasofoxifene in ER+/HER2- Breast Cancer

October 7th 2022

Matthew P. Goetz, MD, discusses the clinical significance of the phase 2 ELAINE-1 trial of lasofoxifene in patients with ESR1-mutated, estrogen receptor-positive/HER2-negative metastatic breast cancer.

Dr. Danilov on the Differences Between Covalent and Noncovalent BTK Inhibitors in MCL

October 7th 2022

Alexey V. Danilov, MD, PhD, discusses the key differences between covalent and noncovalent BTK inhibitors in mantle cell lymphoma.

Dr. Dasari on the Investigation of Fruquintinib in mCRC

October 6th 2022

Nageshwara Arvind Dasari, MD, discusses the patient population observed in the phase 3 FRESCO-2 trial in metastatic colorectal cancer.

Dr. Saba on Disparities of Clinical Trials in Head and Neck Cancer

October 6th 2022

Nabil Saba, MD, FACP, discusses the disparities seen in clinical trials in head and neck cancer.

Dr. Cristofanilli on Optimal Targeted Therapies in Metastatic HR-Positive Breast Cancer

October 5th 2022

Massimo Cristofanilli, MD, discusses the variety of targeted therapies available in metastatic hormone receptor–positive breast cancer.

Dr. Marshall on Genetic Testing in Gastrointestinal Cancer

October 5th 2022

John L. Marshall, MD, discusses the evolution of genetic testing in gastrointestinal cancer.

Dr. Cohen on the Treatment of Patients with Additional Comorbidities in CLL

October 5th 2022

Jonathon B. Cohen, MD, MS, discusses the evolution of treating patients with additional comorbidities in chronic lymphocytic leukemia.

Dr. Desai on Immune Checkpoint Inhibitors with Chemoradiation in Urothelial Cancer

October 5th 2022

Neil Desai, MD, discusses the investigation of immune checkpoint inhibitors with chemoradiation in urothelial cancer.

Dr. Pakkala on Clinical Trial Enrollment for Patients With Breast Cancer and Brain Metastases

October 5th 2022

Suchita Pakkala, MD, discusses the importance for clinical trial enrollment for patients with breast cancer who have brain metastases.